Change over period: —
NSE · SUNPHARMA
SUN PHARMA.
-6.5% from the 52-week high · +17.8% above the low
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra and currently employs 41,000 full-time employees. The firm is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). The company produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The firm's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The firm also has a product portfolio in RoW markets, including injectables, hospital products and retail products. The company offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.
The short version. SUN PHARMA. reported revenue of ₹16,199 crore for Sep 2026, up 11.9% from a year earlier. Net profit was ₹1,989 crore (down 36.2% year on year). Return on equity was 13.7% in Mar 2026. Promoter holding was 52.68% in Sep 2026, down 1.80 points over 8 quarters.
1 · The price
How has the stock traded?
SUN PHARMA. trades 6.5% below its 52-week high and 17.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹16,199 cr.
Sep 2026 net profit of ₹1,989 cr.
9.2 pts lower than a year earlier.
Revenue compounded at 10.7% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16199 | 15300 | 14612 | 15521 | 14478 | 13851 | 12959 | 13675 |
| Net profit | 1989 | 2895 | 2714 | 3369 | 3118 | 2279 | 2150 | 2903 |
| Net margin % | 12.3 | 18.9 | 18.6 | 21.7 | 21.5 | 16.5 | 16.6 | 21.2 |
| EPS (₹) | 8.29 | 12.06 | 11.31 | 14.04 | 13.0 | 9.5 | 8.96 | 12.1 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 58462 | 52578 | 48497 | 43886 | 38654 | 33498 | 32838 | 29066 |
| Net profit | 11479 | 10929 | 9576 | 8474 | 3273 | 2904 | 3765 | 2665 |
| Net margin % | 19.6 | 20.8 | 19.7 | 19.3 | 8.5 | 8.7 | 11.5 | 9.2 |
| EPS (₹) | 47.84 | 45.55 | 39.91 | 35.32 | 13.64 | 12.1 | 15.69 | 11.11 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 13.7% in Mar 2026; debt to equity is 0.05.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 13.7 | 15.1 | 15.0 | 15.1 |
| Return on capital % | 17.9 | 18.9 | 16.5 | 15.8 |
| EBITDA margin % | 30.4 | 30.4 | 27.9 | 27.2 |
| Net margin % | 19.0 | 20.0 | 19.2 | 19.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 10.7% | 12.0% |
| Profit CAGR | 10.7% | 31.6% |
4 · The owners
Who holds it, and are they adding?
Down 1.8 pts over 8 quarters.
Down 3.69 pts over 8 quarters.
Up 3.72 pts over 8 quarters.
+97 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 52.68 | -1.8 |
| FII | 18.05 | 17.96 | 17.26 | 16.55 | 16.12 | 15.93 | 14.53 | 14.36 | -3.69 |
| DII | 18.55 | 18.7 | 19.5 | 20.23 | 20.82 | 21.11 | 22.18 | 22.27 | +3.72 |
| Public | 8.92 | 8.87 | 8.77 | 8.73 | 8.58 | 8.48 | 8.81 | 10.7 | +1.78 |
Mutual fund holdings · Oct 2026
519 schemes hold this stock
422 the month before.
- ICICI Prudential Nifty Pharma ETF18.62% of NAV
- Nippon India Nifty Pharma ETF18.61% of NAV
- ICICI Prudential Nifty Pharma Index Fund18.6% of NAV
- ICICI Prudential Nifty Healthcare ETF16.33% of NAV
- ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF16.32% of NAV
- Axis NIFTY Healthcare ETF16.32% of NAV
- DSP Nifty Healthcare Index Fund16.32% of NAV
- DSP Nifty Healthcare ETF16.31% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SUN PHARMA. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SUN PHARMA.
What is the SUN PHARMA. share price?
SUN PHARMA. (SUNPHARMA) last closed at ₹1,912.30, up 2.18% on the day. Its 52-week range is ₹1,589.30 to ₹2,001.10.
What is the market cap of SUN PHARMA.?
SUN PHARMA. has a market capitalisation of about ₹449,227 crore. Its price-to-earnings ratio is 38.9.
How are SUN PHARMA.'s latest results?
SUN PHARMA. reported revenue of ₹16,199 crore for Sep 2026, up 11.9% from a year earlier. Net profit was ₹1,989 crore (down 36.2% year on year). Return on equity was 13.7% in Mar 2026. Promoter holding was 52.68% in Sep 2026, down 1.80 points over 8 quarters.
Who owns SUN PHARMA.?
As of Sep 2026, shareholding was: Promoter 52.68%, FII 14.36%, DII 22.27%, Public 10.7%.
How many mutual funds hold SUN PHARMA.?
519 mutual fund schemes held SUN PHARMA. in October 2026. That compares with 422 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 07 Jul 2026 · Final Dividend - Rs. 5
- 05 Feb 2026 · Interim Dividend - Rs. 11
- 07 Jul 2025 · Final Dividend - Rs. 5.5
- 06 Feb 2025 · Interim Dividend - Rs. 10.5
- 12 Jul 2024 · Final Dividend - Rs. 5
- 09 Feb 2024 · Interim Dividend - Rs. 8.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.